Mor Eyal, Apte Sameer, Mitchell Catherine, Nessim Carolyn, Almond Max, Vincenzi Bruno, Lopez Jose Antonio Gonzalez, Cranmer Lee, Wagner Michael J, Nissan Aviram, Abreu Miguel Henriques, Albertsmeier Markus, Knoblauch Mathilda, Barlow Adam, Keung Emily Z, Grignani Giovanni, Hornick Jason L, Gronchi Alessandro, Gyorki David E
Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.
Sheba Medical Center, Ramat-Gan, Israel.
Ann Surg Oncol. 2025 Jul 14. doi: 10.1245/s10434-025-17787-8.
Perivascular epithelioid cell tumors (PEComa) are a rare family of mesenchymal tumors that include several subtypes. There are very limited data describing the natural history of patients with extra-visceral retroperitoneal PEComas of the retroperitoneum. The aim of this study is to describe the clinical features, treatment patterns, outcomes, and diagnostic challenges of primary extra-visceral retroperitoneal or abdominopelvic PEComa over the past decade.
This is a retrospective analysis of all extra-visceral, non-renal, retroperitoneal, or abdominopelvic PEComas treated at participating centers over the past 10 years.
A total of 77 patients from 13 centers were included. The median age at diagnosis was 56 years (range 18-81 years); 73% were female. The median size was 9 cm. The tumor was classified as a PEComa not otherwise specified (NOS) in 55 (71%), sclerosing PEComa in 11 (15%), and angiomyolipoma (AML) in 11 (15%). Treatment intent was curative in 59 (77%) patients. Adjuvant radiation was given in five (8%) patients, and (neo)adjuvant systemic therapy was given to six (10%). Of those who did not undergo curative intent treatment, four (22%) patients had metastatic disease and three (17%) had primary unresectable disease. With a median follow-up of 26 months (2.3-147 months), 24 (40%) of the 59 patients having curative treatment had recurred. Recurrence rates differed by subtype, with 20 (37%) of the PEComa NOS group, 3 (27%) of the sclerosing PEComa group, and 1 (9%) of the AML group developing recurrence. The estimated 5-year OS of the whole cohort was 63% and 75% for the curative intent group.
Retroperitoneal and abdominopelvic PEComas show distinct behaviors by subtype. PEComa NOS had the highest recurrence and mortality, sclerosing PEComa showed intermediate risk, and AML was indolent. Histological classification is essential for prognosis and management.
血管周上皮样细胞肿瘤(PEComa)是一类罕见的间叶组织肿瘤,包含多种亚型。关于腹膜后非内脏型PEComa患者的自然病史,相关数据非常有限。本研究旨在描述过去十年原发性腹膜后或腹盆腔非内脏型PEComa的临床特征、治疗模式、治疗结果及诊断挑战。
这是一项对过去10年在参与研究的中心接受治疗的所有腹膜后、非肾脏、非内脏型或腹盆腔PEComa患者的回顾性分析。
共纳入来自13个中心的77例患者。诊断时的中位年龄为56岁(范围18 - 81岁);73%为女性。肿瘤中位大小为9厘米。55例(71%)肿瘤被分类为未另行指定的PEComa(NOS),11例(15%)为硬化性PEComa,11例(15%)为血管平滑肌脂肪瘤(AML)。59例(77%)患者的治疗目的是治愈性的。5例(8%)患者接受了辅助放疗,6例(10%)接受了(新)辅助全身治疗。在未接受治愈性治疗的患者中,4例(22%)有转移性疾病,3例(17%)有原发性不可切除疾病。中位随访时间为26个月(2.3 - 147个月),59例接受治愈性治疗的患者中有24例(40%)复发。复发率因亚型而异,PEComa NOS组20例(37%)复发,硬化性PEComa组3例(27%)复发,AML组1例(9%)复发。整个队列的估计5年总生存率为63%,治愈性治疗组为75%。
腹膜后和腹盆腔PEComa各亚型表现出不同的生物学行为。PEComa NOS复发率和死亡率最高,硬化性PEComa风险中等,AML生长缓慢。组织学分类对预后和治疗管理至关重要。